# Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS).

> **NCT02868580** · PHASE2 · COMPLETED · sponsor: **Neuroscience Trials Australia** · enrollment: 43 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Triumeq

## Key facts

- **NCT ID:** NCT02868580
- **Lead sponsor:** Neuroscience Trials Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2017-12
- **Final completion:** 2018-12
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2019-08-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02868580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02868580, "Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS).". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02868580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*